Metis TechBio signs global licensing deal for biologic drug worth up to $1.6 billion
30/06/2026 05:26
Metis TechBio signs global licensing deal for biologic drug worth up to $1.6 billion June 30 (Reuters) - Hong Kong-listed Metis TechBio said on Tuesday it has granted U.S.-based biotechnology firm Boulevard Bio exclusive global rights to develop, manufacture and commercialise its experimental biologic drug MTS-128 in a deal that could be worth up to $1.6 billion.
(Reporting by Rajasik Mukherjee in Bengaluru; Editing by Janane Venkatraman)
Recent news on Metis TechBio
See all newsFactbox: Pharma sector doubles down on AI to slash costs, timelines
HK-listed Metis TechBio climbs on deal with Eli Lilly
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Metis TechBio, Eli Lilly strike drug-delivery deal worth up to $1.1 billion (updated)
Metis TechBio inks up to $1.1 billion deal with Eli Lilly for drug delivery tech